Shimada

Shimada
[[File:|250px|]]
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms
Complications
Onset
Duration
Types	N/A
Causes
Risks
Diagnosis
Differential diagnosis
Prevention	N/A
Treatment
Medication	N/A
Prognosis
Frequency
Deaths	N/A

Shimada is a term used in the context of neuroblastoma, a type of cancer that most commonly affects children. The term refers to the histopathological classification of neuroblastoma tumors based on the degree of differentiation and the presence of certain cellular features. This classification is crucial for determining the prognosis and treatment strategy for patients diagnosed with neuroblastoma.

Histopathological Classification

The Shimada classification system, named after Dr. Hiroyuki Shimada, is used to categorize neuroblastoma tumors into "favorable" and "unfavorable" histology. This classification is based on the following criteria:

• Differentiation: The degree to which tumor cells resemble normal cells. Tumors can be classified as undifferentiated, poorly differentiated, or differentiating.
• Stroma: The presence of Schwannian stroma, which is supportive tissue that can indicate a more favorable prognosis.
• Mitosis-Karyorrhexis Index (MKI): A measure of the number of cells undergoing division and cell death. A lower MKI is associated with a more favorable prognosis.

Favorable Histology

Tumors with favorable histology typically have a higher degree of differentiation, abundant Schwannian stroma, and a low MKI. These tumors are associated with a better prognosis and may require less aggressive treatment.

Unfavorable Histology

Unfavorable histology is characterized by undifferentiated or poorly differentiated cells, scant Schwannian stroma, and a high MKI. These tumors are associated with a poorer prognosis and often require more aggressive treatment.

Clinical Implications

The Shimada classification is an important tool in the management of neuroblastoma. It helps oncologists determine the aggressiveness of the disease and tailor treatment plans accordingly. Patients with favorable histology may be candidates for less intensive therapy, while those with unfavorable histology may require more aggressive treatment, including chemotherapy, radiation, and possibly stem cell transplantation.

Research and Developments

Ongoing research in the field of neuroblastoma aims to refine the Shimada classification and improve the accuracy of prognosis predictions. Advances in molecular biology and genetics are contributing to a better understanding of the disease and may lead to more personalized treatment approaches in the future.

Also see

• Neuroblastoma
• Oncology
• Histopathology
• Cancer staging